Hydrochloric Acid → 4-cyclopropyl-2-(5-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyrimidine-5-carboxylic acid

HRID 634308노트

반응식

HRID 634308 반응식
[CH:1]1([C:4]2[C:9]([C:10]([O:12]C)=[O:11])=[CH:8][N:7]=[C:6]([C:14]3[C:22]4[C:17](=[CH:18][CH:19]=[C:20]([C:23]5[O:24][C:25]([NH:28][CH:29]([CH3:31])[CH3:30])=[N:26][N:27]=5)[CH:21]=4)[N:16]([S:32]([C:35]4[CH:41]=[CH:40][C:38]([CH3:39])=[CH:37][CH:36]=4)(=[O:34])=[O:33])[CH:15]=3)[N:5]=2)[CH2:3][CH2:2]1.C1COCC1.O.[OH-].[Li+].Cl>O>[CH:1]1([C:4]2[C:9]([C:10]([OH:12])=[O:11])=[CH:8][N:7]=[C:6]([C:14]3[C:22]4[C:17](=[CH:18][CH:19]=[C:20]([C:23]5[O:24][C:25]([NH:28][CH:29]([CH3:31])[CH3:30])=[N:26][N:27]=5)[CH:21]=4)[N:16]([S:32]([C:35]4[CH:41]=[CH:40][C:38]([CH3:39])=[CH:37][CH:36]=4)(=[O:33])=[O:34])[CH:15]=3)[N:5]=2)[CH2:3][CH2:2]1

참가 물질

6

반응물 4

HCID 313Hydrochloric AcidHCID 8028TetrahydrofuranHCID 168937Lithium hydroxide, monohydrateHCID 68328004HCID 68328004, 화합물

생성물 1

HCID 683286994-cyclopropyl-2-(5-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyrimidine-5-carboxylic acid

시약·촉매·용매 1

HCID 962Water용매

실험 절차

Methyl 4-cyclopropyl-2-(5-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyrimidine-5-carboxylate (110 mg, 0.192 mmol) was treated with THF (2 mL), water (1.0 mL) and lithium hydroxide monohydrate (20 mg, 0.48 mmol) and stirred at RT for 1.5 h. The reaction mixture was treated with a 5 N HCl (0.5 mL) and concentrated on the rotovap. It was then dried further by azeotroping with toluene and drying under high vacuum at 50° C. for 3 h. MS (ESI, pos. ion) m/z: 559.0 (M+H)+. It was then used in the subsequent step with further purification.

후처리

  1. concentrationconcentrated on the rotovap
  2. customIt was then dried further
  3. customby azeotroping with toluene
  4. customdrying under high vacuum at 50° C. for 3 h
  5. customIt was then used in the subsequent step with further purification

출처 및 근거

ORD 기록
ord-77b2e696054c4d599e950d05d5de1023
출처 데이터셋
uspto-grants-2016_04
특허 번호
US09321756B2

반응 노트

불러오는 중…